

# PPD® – An Experienced Cardiovascular Partner



Bringing cardiovascular drugs to the marketplace comes with a unique set of challenges. PPD has extensive global experience in planning, implementing, accelerating and delivering Phase I-IV cardiovascular clinical trials across a broad range of drug classes to help you overcome these challenges.

## PARTNER WITH PPD AND BENEFIT FROM OUR:

- **Depth of experience** across all stages of cardiovascular drug development
- Identifying older populations through our global network of **160+ dedicated research sites**
- Decentralized and digital trial solutions that **accelerate recruitment and shorten timelines**
- Recruiting patients with cardiovascular disease, risk factors and comorbidities through our **100-million-household database** of opted-in and fully identified patients
- **Customized digital solutions** built around comorbidities such as cardiac outcome and lipid trials
- Comprehensive, **global central lab** services
- PPD supports clients with seamless, cross-collaborative operational, medical and scientific expertise, including the **acute critical care setting**

## CARDIOVASCULAR CLINICAL RESEARCH EXPERIENCE

### Our global experience:

- Spans early-phase studies through post-approval studies and includes a broad range of indications including hypertension, cardiomyopathy, pulmonary hypertension, rare disease and comorbid metabolic and renal conditions such as chronic kidney disease, T2 diabetes, obesity and hyperlipemia/dyslipidaemia
- Comprehensive end-point adjudication experience across 25 protocols with cardiovascular endpoints including CV outcome studies in both chronic kidney disease, diabetes and obesity
- Includes single-site dose explorations to multi-national outcomes studies and from traditional to novel endpoints

PPD'S DATABASE CONTAINS 3,900 SITES THAT HAVE CONDUCTED CARDIOVASCULAR STUDIES WITH A GLOBAL FOOTPRINT IN THE LAST 5 YEARS



**75** cardiovascular studies



**29,000+** patients



**3,900+** global sites



**17** cardiovascular outcomes and MACE studies

## COMPREHENSIVE CARDIOVASCULAR IMAGING CAPABILITIES

- Cardiac catheterization • Computed tomography (CT) scan • Echocardiography • Exercise stress testing
- Magnetic resonance angiography (MRA) • Magnetic resonance imaging (MRI) • Multigated acquisition scan (MUGA) imaging
    - Positron emission tomography (PET) pharmacologic and stress / rest perfusion, as well as metabolic imaging
      - Pharmacologic stress testing • Stress echocardiography • Technetium 99m stress/rest imaging
  - Thallium 201 stress/rest imaging • Transesophageal echocardiography (TEE) • Cardiac MRIs • CPET (exercise stress testing)

## EASING ENROLLMENT AND INCREASING RETENTION WITH PATIENT-CENTRIC SERVICES

We recognize how challenging managing clinical trial burdens can be for patients and their caregivers.

We provide concierge services to make it easier for patients to participate in trials by offering:



**Telemedicine, Mobile Units and Home Healthcare Services**



**Digital and Decentralized Protocols**



**Transportation Coordination and Verification**



**eCOA/ePRO**



**Flexible Reimbursement Options**



**Wearables and Mobile Pages**

These services help to **increase patient access to clinical trials** in addition to producing **timely and high-quality data** for our clients while **saving patients time and cost**.

Our patient-centric approach has led to over 90% patient retention over five years for a recent long-term follow-up trial. To simplify recruitment, PPD offers accelerated enrollment solutions (AES) that give access to a **robust and ever-expanding patient database** including patients with rare conditions



**Scan to  
Learn  
More**

## LEVERAGING TECHNOLOGICAL INSIGHTS FOR PROACTIVE STUDY DESIGN

Our clinical trial simulator can help you identify potential gaps in your program ahead of time. We help you use its insights to guide the selection of design parameters for clinical trials

## REGULATORY STRATEGIES TO SUPPORT SUCCESSFUL FILINGS

Our global regulatory experts have expertise in early and frequent collaboration with regulators to ensure successful submissions for cardiovascular indications. We can support you with protocols for:

- Early planning Real World Evidence (RWE) generation
- Natural history, registry and endpoint development and analysis